Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Public ClinicalTrials.gov record NCT05422911. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized Study of Abiraterone Acetate, Enzalutamide or Apalutamide as First Line Therapy in Veterans With Castrate-sensitive Prostate Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurately predict OS and the use of this metric in other settings should now be explored. In the egalitarian system that is the VHA the treatment of prostate cancer is excellent and uniform across the US. The choices made are clearly personalized, given not all men received all therapies and that younger Veterans were treated more aggressively. But with survivals that rival those in registration trials that enroll optimally fit individuals usually not encumbered by the co-morbidities that afflict many Veterans, the outcomes are testimony to the fact that for this common malady of older Veterans with whom VA physicians have broad experience the care administered is unsurpassed. Importantly this care at least as regards Veterans with mCRPC demonstrates that given equal access to health care, all men with prostate cancer fare comparably well. As our sophistication in categorizing cancers molecularly has increased this study will look to better examine any emerging differences across study participants.
Study identification
- NCT ID
- NCT05422911
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 192 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2022
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2027
- Last update posted
- Jun 14, 2026
2022 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| VA Greater Los Angeles Healthcare System | Los Angeles | California | 90073 | Recruiting |
| James A. Haley Veterans Administration Hospital | Tampa | Florida | 33612 | Recruiting |
| VA Ann Arbor Healthcare System | Ann Arbor | Michigan | 48105 | Recruiting |
| VA St. Louis Health Care System | St Louis | Missouri | 63106 | Recruiting |
| VA New York Harbor Healthcare System | New York | New York | 10010 | Recruiting |
| James J. Peters VA Medical Center | The Bronx | New York | 10468 | Recruiting |
| VA Hudson Valley Health Care System | Wappingers Falls | New York | 12590 | Recruiting |
| W.G. Bill Hefner Medical Center | Salisbury | North Carolina | 28144 | Recruiting |
| VA Portland Health Care System | Portland | Oregon | 97239 | Recruiting |
| Corporal Michael J. Crescenz VA Medical Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Michael E. DeBakey VA Medical Center | Houston | Texas | 77030 | Recruiting |
| VA Puget Sound Health Care System | Seattle | Washington | 98108 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05422911, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 14, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05422911 live on ClinicalTrials.gov.